Real-World Anti-VEGF Practices in Pakistan: A Nationwide Study of Ophthalmologists' Practice Patterns and Challenges
DOI:
https://doi.org/10.51253/pafmj.v76iSUPPL-8.14286Keywords:
Anti-VEGF Therapy, Avastin, Bevacizumab, Endophthalmitis, Intravitreal InjectionAbstract
Objective: To evaluate practice patterns and safety protocols related to intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections among ophthalmologists in Pakistan, and to assess the perceived clinical and economic impact of the ban on bevacizumab in Punjab province.
Study Design: Cross-sectional study.
Place and Duration of Study: Nationwide study conducted across Pakistan from Oct to Nov 2024.
Methodology: A structured 30-item questionnaire was distributed electronically to 160 ophthalmologists through Pakistan Vitreo-Retinal Society. Participation was voluntary and anonymous. Frequencies and percentages were calculated for different variables.
Results: A total of 100 ophthalmologists responded. Practice settings included private practice (52%), Trust-based facilities (40%), and government hospitals (8%). Bevacizumab was the most frequently used agent (68%), followed by aflibercept (29%) and ranibizumab (3%). Seventy-four percent of practitioners indicated that they employed multi dose vial practices for administering aflibercept and ranibizumab injections. For administering injections, 92% practitioners preferred topical anesthesia, 90% used conjunctival sac povidone iodine, while 90% prescribed post-injection topical antibiotics for a week. Seventy-six percent of ophthalmologists preferred to use pre-filled, sterilized, single dose of bevacizumab injection meeting FDA compounding standards. Special informed consent for off-label bevacizumab use was obtained by 48% of respondents. Following the bevacizumab ban in Punjab, 93% (53 out of 57) respondents reported shifting to alternative therapies while 82.5% (47 out of 57) perceived significantly worsening patient outcomes.
Conclusion: Significant variability exists regarding the intravitreal anti-VEGF practices in Pakistan. The bevacizumab ban had substantial perceived impact on treatment accessibility and affordability.
Downloads
References
1. American Diabetes Association Professional Practice Committee. Retinopathy, neuropathy, and foot care: standards of care in diabetes—2026. Diabetes Care 2026; 49(Suppl 1): S261-S276.
https://doi.org/10.2337/dc26-S012
2. Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Ophthalmology 2017; 124(3): 352-358. https://doi.org/10.1016/j.ophtha.2016.10.036
3. Sundar D, Das T, Chhablani J, Kumar A, Sharma N. All India Ophthalmological Society members' survey: Practice pattern of intravitreal anti-vascular endothelial growth factor injection. Indian J Ophthalmol 2020; 68(6): 1095-1099.
https://doi.org/10.4103/ijo.IJO_1850_19
4. Shanmugam PM. Changing paradigms of anti-VEGF in the Indian scenario. Indian J Ophthalmol 2014; 62(1): 88-92.
https://doi.org/10.4103/0301-4738.126191
5. Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology 2016; 123(6): 1351-1359.
https://doi.org/10.1016/j.ophtha.2016.02.022
6. Mason JO, White MF, Feist RM, Thomley ML, Albert MA, Persaud TO, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina. 2008; 28(4): 564-567.
https://doi.org/10.1097/IAE.0b013e3181657621
7. Dossarps D, Bron AM, Koehrer P, Aho-Glélé LS, Creuzot-Garcher C, Berthon L, et al. Endophthalmitis After Intravitreal Injections: Incidence, Presentation, Management, and Visual Outcome. Am J Ophthalmol 2015; 160(1): 17-25.
https://doi.org/10.1016/j.ajo.2015.04.013
8. Khaqan HA, Khan T, Tayyab H, Marwat TK, Lateef MQ, Tayyab M. Complications of different intravitreal anti VEGF injections at multiple centers observing different protocols. Pak J Ophthalmol 2019; 35(1): 25-30. https://doi.org/10.36351/pjo.v35i1.878
9. Punjab Healthcare Commission. Guidelines for intravitreal injections [Internet]. Lahore: Punjab Healthcare Commission; 2023 [cited 2026 Mar 10]. Report No.: PHC/CG&OS/CM/2023/242. Available from:
10. Schwartz SG, Flynn HW. Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Curr Ophthalmol Rep 2014; 2(1): 1-5.
https://doi.org/10.1007/s40135-013-0033-1
11. Feng HL, Abdelwahab S, Imam N, Astafurov K, Roth DB. Reduced Incidence of Intravitreal Injection-Related Endophthalmitis With Prefilled Syringes. J Vitreoretin Dis 2023; 7(4): 305-309. https://doi.org/10.1177/24741264231170751
12. Uzzan J, Mapani A, Cox O, Bagijn M, Saffar I. Clinical Outcomes and Experiences with Prefilled Syringes Versus Vials for Intravitreal Administration of Anti-VEGF Treatments: A Systematic Review. Ophthalmol Ther 2024; 13(9): 2445-2465.
https://doi.org/10.1007/s40123-024-01002-0
13. Gjølberg TT, Lode HE, Melo GB, Mester S, Probst C, Sivertsen MS, et al. A silicone oil-free syringe tailored for intravitreal injection of biologics. Front Ophthalmol 2022; 2: 882013.
https://doi.org/10.3389/fopht.2022.882013
14. Riaz S, Khan MT, Chaudhry QL, Chaudhry SL, Munir F. Real-World Indications for Intravitreal Anti-VEGF Injections in Tertiary Eye Care Hospitals: A Multi-Center Study. Pak J Ophthalmol 2025; 41(3).
https://doi.org/10.36351/pjo.v41i3.1994
15. Avery R, Bakri S, Blumenkranz M, Brucker A, Cunningham E, DʼAmico D, et al. Intravitreal Injection Technique and Monitoring. Retina 2014; 34(Suppl): S1-S18.
https://doi.org/10.1097/IAE.0000000000000399
16. Royal College of Ophthalmologists. Ophthalmic Service Guidance: Intravitreal injection therapy. London: RCOphth; 2018 [cited 2026 Mar 10]. Available from:
17. Ghasemi FK, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature. Eye 2013; 27(7): 787-794.
https://doi.org/10.1038/eye.2013.107
18. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011; 56(2): 95-113.
https://doi.org/10.1016/j.survophthal.2010.08.006
19. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69(Suppl 3): 25-33. https://doi.org/10.1159/000088481
20. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, et al. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 2012; 7(8): e42701.
https://doi.org/10.1371/journal.pone.0042701
21. The Royal College of Ophthalmologists. Intravitreal injections consent and checklist recommendations. London: RCOphth; 2024. [Accessed April 19, 2026]. Available from:
22. Ali SM, Iqbal A, Hamid Z, Rauf SA, Haque MA. Off-label use of Avastin in Pakistan: Lessons from the 2023 Punjab outbreak. J Public Health Res 2025; 14(3): 22799036251361620.
https://doi.org/10.1177/22799036251361620
23. Sam-Oyerinde OA, Patel PJ. Real-World Outcomes of Anti-VEGF Therapy in Diabetic Macular Oedema: Barriers to Treatment Success and Implications for Low/Lower-Middle-Income Countries. Ophthalmol Ther 2023; 12(2): 809-826.
Downloads
Published
License
Copyright (c) 2026 Mahwish Shahid, Fiza Shaheen, Muhammad Amjad, Huzaifa Farooq, Yasir Ahmad, Sarah Zafar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
